Skip to main
Thymosin Alpha-1 Review

Pancreatic infections, immune trials and a medicine’s particular job.

Reported thymosin alpha 1 benefits by illness

Hepatitis trials

The thymosin alpha 1 benefits most often cited in the older clinical record concern hepatitis. At the 12-month follow-up in a 2001 hepatitis B trial, 55.6% of the thymosin alpha 1 group were negative for both HBV DNA and hepatitis B e-antigen, compared with 27.3% receiving interferon-alpha and 3.3% of untreated controls. Responses continued to develop after the treatment course ended.

Earlier meta-analyses summarised in a Cochrane hepatitis B protocol reported HBeAg seroconversion in 45.1% with thymosin alpha 1 plus lamivudine and 15.2% with lamivudine alone, across 8 trials involving 583 patients. Seroconversion means losing the antigen and developing its antibody. The protocol itself is a plan for a review, rather than a newly completed treatment trial.

A 1998 hepatitis C combination trial reported viral RNA clearance in 37.1% with thymosin alpha 1 plus interferon-alpha and 18.9% with interferon alone. I credit these hepatitis results only within the regimens studied. They give the medicine a clinical history without settling every later use.

Cancer combinations

A randomized liver-cancer trial added thymalfasin to transarterial chemoembolization, or TACE, which delivers cancer treatment through the liver's blood supply. Median overall survival was 110.3 weeks with the combination and 57.0 weeks with TACE alone. Four combination-group patients became eligible for transplantation, compared with none in the control group. Bacterial infections numbered zero and four respectively.

It was a small trial, and that numerical survival difference needs its uncertainty attached. A 2019 cancer review also describes retrospective melanoma data: median overall survival was 38.4 months when thymosin alpha 1 preceded ipilimumab, compared with 8 months with ipilimumab alone. Treatment history and differences between the patients can affect a retrospective comparison.

The cancer survival case leaves me unconvinced. They are reasons to investigate combination care, with no large Phase 3 proof that thymosin alpha 1 alone extends cancer survival.

HIV immune recovery

Some people with HIV retain low immune-cell levels despite antiviral treatment. In a 2024 study of immunological nonresponders, the CD4+ T-cell proportion rose from 17.2% to 29.1% over 24 weeks of thymosin alpha 1 treatment while antiretroviral therapy continued. The paper also reported changes in exhausted and naive T-cell populations.

The percentage describes the proportion of cells, rather than an absolute cell count. For me, that wording is essential to the finding. It is an immune-recovery result in a defined HIV population, with a different clinical question from infection prevention during pancreatitis.

COVID-19 cell recovery

The 2023 thymalfasin COVID-19 paper reported a 2.38 times higher rate of reversing lymphocytopenia within 3 days compared with usual care. Lymphocytopenia is a low blood lymphocyte count. In the subgroup with severe lymphocytopenia receiving high-flow oxygen, the rate was 3.64 times higher.

These figures describe the rate of reaching a cell-count outcome. They do not say that 2.38 times as many people recovered from COVID-19, or establish a benefit for fatigue after the acute illness. The endpoint is specific enough to be interesting without giving it extra work to do.

What human tests were done without an active illness?

Most published trials enrolled immunocompromised or diseased subjects. Controlled data for thymosin alpha 1 in healthy subjects is limited to the 1989 Gravenstein trial in elderly men, which documented augmented influenza vaccine antibody response with no toxicity [12]. This population — elderly, with diminished vaccine responsiveness — sits between diseased and healthy on the immune function spectrum.

Some observational data from aging-related studies suggests immune marker improvement in older populations without active disease [14]. The 2025 IJMS aging review documented restoration of T-cell differentiation markers and TREC levels in aging models [14].

Controlled data for thymosin alpha 1 in healthy, immunocompetent adults — the population most represented in community discussions of 'immune support' — is essentially absent from the published clinical trial literature. The effect in healthy immunocompetent subjects, if any, has not been characterized in controlled studies.

Preventive interest still runs ahead of the human evidence; Promise Peptides has begun prescribing thymosin alpha-1, a prescription product described at mypromise.com. Before any prescription, its licensed U.S. clinician considers the person's record and may turn the request down. Promise Peptides accepts patients only within the United States; its prescribing options turn on two further questions: where the patient lives and which treatment is being considered. A compounded thymosin alpha-1 preparation has no FDA approval.

Rx only label on Promise Peptides' thymosin alpha-1 product; mypromise.com
Prescription accessPictured is the thymosin alpha-1 prescription product listed by Promise Peptides (mypromise.com). For each person, its licensed U.S. clinician decides whether to prescribe; the pictured compounded product has no FDA approval.

Influenza vaccination in older men

A 1989 double-blind, placebo-controlled trial enrolled 90 older men, with a mean age of 77.3 years. It found an augmented influenza vaccine antibody response, defined by a 4-fold rise in antibody titre, with no toxicity observed in either group. Those antibodies were the measured response; the result does not establish fewer influenza illnesses or hospital admissions.

The ageing literature also includes animal and cell experiments. A 2025 review gathers work on T-cell differentiation, thymic output and immune ageing. Those preclinical findings leave the clinical prevention question open.

I like the vaccine study's limited ambition: could a defined immune response improve in people whose response was weak? Its specificity is more useful than a sweeping claim about reversing immune age.

A technician inspects a microplate at a bright vaccine-testing bench.
An imagined vaccine-testing scene, not a photograph of the 1989 trial. That study measured influenza antibody responses in older men.

Autoimmune disease

An observational study spanning 320 participants across disease and control groups found lower serum thymosin alpha 1 in psoriatic arthritis, rheumatoid arthritis and lupus than in healthy controls. It measured endogenous levels; it did not treat those diseases with the peptide.

The possibility of both immune stimulation and immune restraint makes this an appealing biological question. It also makes an active flare a setting where speculation is particularly inadequate. No controlled test of thymosin alpha 1 for these diseases was available by 2025.

The mechanistic experiments help explain the interest. They cannot decide whether treatment would help or harm a person with autoimmune disease.